静脉注射免疫球蛋白在系统性硬化症(SSc)中的作用:一项系统性文献综述
该系统性文献综述检索了2003年1月1日至2024年4月15日的五个数据库,纳入12项研究共266例接受静脉注射免疫球蛋白(IVIG)的成人系统性硬化症(SSc)患者,涉及皮肤、呼吸、肌肉骨骼、胃肠道及其他结局。IVIG在减轻皮肤增厚、肌肉关节疼痛、胃肠道症状、减少激素用量及改善生活质量方面显示有利效果,但对呼吸系统疾病可能获益较少;因缺乏高质量研究且多数研究合并使用其他治疗,IVIG单药疗效难以确定。
要点
- IVIG在减轻SSc皮肤增厚程度、肌肉和关节疼痛、胃肠道症状及减少激素剂量方面显示有利效果。
- IVIG对SSc呼吸系统疾病可能获益较少,但肺功能检查和影像学特征的稳定本身可视为积极结局。
- 缺乏高质量研究且多数研究合并使用其他治疗,IVIG单药疗效难以确定,需进一步设计良好的临床试验。
核心结论
- IVIG对SSc的某些表现有获益,但对其他表现的疗效缺乏令人信服的证据。
- 缺乏高质量数据,凸显需要进一步设计良好的临床试验来确认这些发现并为IVIG使用指南提供依据。
研究设计与样本
- 系统文献综述,检索Medline、Embase、Cochrane、Web of Science和Scopus从2003年1月1日至2024年4月15日的文献。
- 纳入标准为英文全文、≥5例成人SSc患者接受IVIG且有可报告结局记录的研究。
- 从418条可能相关的记录中纳入12项研究,共266例患者,包括1项随机对照试验、2项先导研究、1项开放标签研究、7项回顾性研究和1项病例对照研究。
主要发现
- 记录了18项结局,涉及五个不同器官系统:皮肤、呼吸、肌肉骨骼、胃肠道及其他(临床改善和减少激素用量获益)。
- 结果显示IVIG在减轻皮肤增厚程度、肌肉和关节疼痛、胃肠道症状、激素剂量及改善患者/医生报告的生活质量方面有有利效果。
- IVIG对呼吸系统疾病可能获益较少,但肺功能检查和影像学特征的稳定本身可视为积极结局。
关键数值与推荐
- 纳入研究需为英文全文、≥5例成人SSc患者接受IVIG且有可报告结局记录。
- 共纳入12项研究、266例患者,包括1项随机对照试验、2项先导研究、1项开放标签研究、7项回顾性研究和1项病例对照研究。
- 记录了18项结局,涉及皮肤、呼吸、肌肉骨骼、胃肠道及其他五个器官系统。
临床怎么用
- 原文未据此给出推荐。
局限性
- 缺乏高质量研究。
- 许多研究使用合并治疗,使得IVIG单药疗效难以确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systemic sclerosis (SSc) is a heterogenous, multi-system autoimmune disease that causes progressive fibrosis of the skin and internal organs, resulting in high morbidity and mortality. Intravenous Immunoglobulin (IVIG) is a therapeutic option for SSc; however, reports of its efficacy have been variable, and its use across multiple organ manifestations of SSc has not been comprehensively reviewed. AIM: The aim of this study was to systematically assess the existing literature on the role of IVIG use across a range of SSc manifestations. METHODS: Medline, Embase, Cochrane, Web of Science and Scopus were searched from 01/01/2003-15/04/2024 using terms related to SSc and IVIG. Included studies were English-language full texts, where ≥5 adults with SSc received IVIG, and where a reportable outcome was documented. RESULTS: Of 418 potentially relevant records, 12 were included in this review, comprising 266 patients across one randomised control trial, two pilot studies, one open label study, seven retrospective studies and one case control study. Eighteen outcomes were documented across five different organ systems: cutaneous, respiratory, musculoskeletal, gastrointestinal, and other (clinical improvement and corticosteroid sparing benefit). Results showed a favourable effect of IVIG in reducing the extent of skin thickening, muscle and joint pain, gastrointestinal symptoms, steroid dosing and improving patient/physician reported quality of life. Whilst IVIG may appear to be less beneficial for respiratory disease, the stabilisation in pulmonary function tests and radiological features may be considered a positive outcome in itself. Limitations included a lack of high-quality studies, and the use of concomitant therapies in many studies, rendering the efficacy of IVIG alone difficult to ascertain. CONCLUSION: IVIG showed benefit in treating some manifestations of SSc, however there was a lack of convincing evidence for the efficacy in others. The lack of high-quality data highlights the need for further well-designed clinical trials to confirm these findings and inform guidelines for IVIG use.
引用
- Koczanowski S, Morrisroe K, Fairley J, et al. Role of intravenous immunoglobulins in systemic sclerosis (SSc): A systematic literature review. Semin Arthritis Rheum. 2024. PMID: 38954999. doi:10.1016/j.semarthrit.2024.152471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。